Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,715 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dried Clear all
Completed Phase 2 Interventional

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07264517
View directory record Official record
Conditions
Dry Eye Disease
Interventions
GRF312 5%, Placebo Comparator
Drug · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Glendale, California • Grove, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

The Effects of Dry Needling on Patients With Knee Pain

NCT02890485
View directory record Official record
Conditions
Patellofemoral Pain Syndrome, Anterior Knee Pain Syndrome
Interventions
Dry Needling, Sham Dry Needling, Physical Therapy
Device · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 28, 2026, 7:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Vonaprument, Sham Administration
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 7:52 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Anti-Glaucoma Medications on the Ocular Surface

NCT01315574
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 28, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

NCT04035668
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01119950
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily, NVA237 50.0 µg once daily, NVA237 25.0 µg twice daily, NVA237 100.0 µg once daily, NVA237 50.0 µg twice daily, Placebo to NVA237 once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Anniston, Alabama • San Diego, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 28, 2026, 7:52 PM EDT
Completed No phase listed Observational Results available

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

NCT03543176
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
Other · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

NCT04450589
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Not applicable Interventional

Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy

NCT00344890
View directory record Official record
Conditions
Cervical Radiculopathy, Myelopathy
Interventions
Anterior Cervical Discectomy and Fusion
Procedure
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Worksite Wellness Randomized Controlled Trial

NCT02593240
View directory record Official record
Conditions
Obesity, Overweight, Quality of Life
Interventions
The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food, The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher, Human Performance Institute©
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
21 Years and older
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alpha MSH in Ocular Disease

NCT03451578
View directory record Official record
Conditions
Advanced Dry Macular Degeneration
Interventions
Alpha MSH assay
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 28, 2026, 7:52 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

NCT07235085
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 7:52 PM EDT
Completed No phase listed Observational

PuraPly™ Antimicrobial Wound Matrix and Wound Management

NCT03070938
View directory record Official record
Conditions
Pressure Ulcer, Venous Ulcer, Diabetic Ulcer, Surgical Wound, Trauma Wound
Interventions
PuraPly™ Antimicrobial Wound Matrix
Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 3 Interventional

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Drug · Other
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

ESBA105 in Patients With Severe Dry Eye

NCT01338610
View directory record Official record
Conditions
Eyes Dry Chronic
Interventions
ESBA105 ophthalmic solution, ESBA105 vehicle
Biological · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 28, 2026, 7:52 PM EDT
Not yet recruiting Not applicable Interventional

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110
View directory record Official record
Conditions
Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions
Ultrafiltration
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

In Vivo Efficacy Study of Patient Preoperative Preps

NCT02203591
View directory record Official record
Conditions
Bacterial Reduction Post-product Application
Interventions
3M CHG/IPA Prep C, 3M CHG/IPA Prep CH, ChloraPrep, Normal Saline
Drug
Lead sponsor
3M
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 28, 2026, 7:52 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 28, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

Standardized Microbiota Transplant Therapy in Crohn's Disease

NCT06631586
View directory record Official record
Conditions
Crohn Disease
Interventions
MTP-101C, MTP-101S
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Minneapolis, Minnesota • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 28, 2026, 7:52 PM EDT